ORAMED PHARMACEUTICALS INC.
Business
Oramed Pharmaceuticals is a pharmaceutical company developing an oral delivery platform technology for therapeutic proteins, with a lead program in oral insulin. The company conducts research and development through clinical trials, including a planned 60-patient US-based trial to validate its oral insulin formulation. Oramed also allocates capital to strategic investments in healthcare and life sciences companies, including stakes in Alpha Tau Medical (oncology), Lifeward (medical robotics), BioXcel Therapeutics (biopharmaceuticals), and other healthcare entities. The company operates primarily in the United States and globally through licensing agreements and joint ventures.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| REVENUES | 2 | — | 1 | 3 | 3 | |
| COST OF REVENUE | −2 | — | — | — | — | |
| GROSS PROFIT | 13,000 | — | — | — | — | |
| RESEARCH AND DEVELOPMENT EXPENSES | −6 | −6 | −9 | −28 | 21 | |
| GENERAL AND ADMINISTRATIVE EXPENSES | −9 | −6 | −8 | −14 | 6 | |
| OPERATING LOSS | −15 | −13 | −16 | −41 | 24 | |
| OTHER INCOME, NET | 958,000 | — | — | — | — | |
| INTEREST EXPENSES (note 12) | — | −853,000 | −2 | — | — | |
| FINANCIAL INCOME (LOSS), NET (note 17) | 89 | −2 | 23 | 3 | — | |
| INCOME (LOSS) BEFORE TAX EXPENSES | 75 | −16 | 5 | −38 | — | |
| TAX EXPENSES | −11 | −3 | — | −100,000 | — | |
| NET INCOME (LOSS) | 64 | −19 | 6 | −38 | 23 | |
| NON-CONTROLLING INTERESTS | −34,000 | −43,000 | −437,000 | −1 | — | |
| COMPANYS STOCKHOLDERS | 64 | −19 | 5 | −37 | 23 | |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share) | 1.53 | −0.48 | 0.14 | −0.94 | — | |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share) | 1.5 | −0.48 | 0.14 | −0.94 | — | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares) | 41 | 41 | 40 | 39 | — | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares) | 42 | 41 | 41 | 39 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 46 | 54 | 9 | 40 | — | |
| Short-term deposits (note 2) | 11 | 55 | 95 | 112 | 111 | |
| Marketable securities (note 3) | 5 | 3 | — | 4 | 8 | |
| Investments at fair value (note 4,7) | 64 | 29 | 58 | — | — | |
| Convertible note (note 9) | 5 | — | — | — | — | |
| Prepaid expenses and other current assets | 3 | 1 | 537,000 | 1 | — | |
| Total current assets | 133 | 143 | 163 | 157 | 148 | |
| Long-term deposits | 2,000 | 2,000 | 7,000 | 7,000 | — | |
| Marketable securities (note 3) | 8 | — | 2 | — | 4 | |
| Investments at fair value (note 4,7) | 10 | 7 | 51 | — | — | |
| Investment in associate at fair value (note 8) | 72 | — | — | — | — | |
| Loan to an equity method investee (note 6) | 553,000 | — | — | — | — | |
| Investment in real estate (note 5) | 2 | — | — | — | — | |
| Other non-marketable equity securities (note 10) | 4 | 4 | — | — | — | |
| Amounts funded in respect of employee rights upon retirement | 44,000 | 32,000 | 27,000 | — | — | |
| Property and equipment, net | 586,000 | 698,000 | 873,000 | 815,000 | 388,000 | |
| Operating lease right of use assets | 750,000 | 414,000 | 694,000 | 987,000 | 500,000 | |
| Total long-term assets | 98 | 12 | 58 | 5 | 30 | |
| Total assets | 231 | 155 | 221 | 162 | 178 | |
| Accounts payable and accrued expenses (note 11) | 6 | 5 | 2 | 4 | 5 | |
| Payable to related parties (note 20) | 652,000 | 329,000 | 325,000 | 1,000 | — | |
| Deferred income (note 8) | 1 | — | — | — | — | |
| Dividend Payable | 11 | — | — | — | — | |
| Operating lease liabilities | 285,000 | 216,000 | 267,000 | 247,000 | 130,000 | |
| Total current liabilities | 19 | 6 | 53 | 6 | 7 | |
| Long-term deferred revenues (note 13) | 2 | 4 | 4 | — | — | |
| Long-term deferred income (note 8) | 1 | — | — | — | — | |
| Employee rights upon retirement | 39,000 | 30,000 | 28,000 | — | — | |
| Operating lease liabilities | 540,000 | 156,000 | 342,000 | 647,000 | 370,000 | |
| Dividend Payable | 275,000 | — | — | — | — | |
| Other liabilities | — | 60,000 | 63,000 | — | — | |
| Deferred tax liabilities (note 18) | 8 | — | — | — | — | |
| Total long-term liabilities | 12 | 4 | 4 | 5 | 4 | |
| COMMITMENTS (note 13) | — | — | — | — | — | |
| Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2025 and December 31, 2024; 39,275,006 and 39,919,545 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | 472,000 | 480,000 | 485,000 | 476,000 | 459,000 | |
| Additional paid-in capital | 323 | 322 | 321 | 314 | — | |
| Accumulated deficit | −123 | −177 | −158 | −163 | −127 | |
| Total stockholders equity | 200 | 146 | 164 | 152 | 166 | |
| Non-controlling interests | — | −918,000 | −928,000 | −656,000 | 157,000 | |
| Total equity | 200 | 145 | 163 | 151 | 167 | |
| Total liabilities and equity | 231 | 155 | 221 | 162 | 178 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Depreciation | 121,000 | 193,000 | 196,000 | 58,000 | 77,000 | |
| Exchange differences and interest on deposits | 830,000 | −3 | −2 | — | — | |
| Changes in fair value of investments | −86 | 7 | — | — | — | |
| Stock-based compensation | 6 | 4 | 4 | 12 | 3 | |
| Gain on amounts funded in respect of employee rights upon retirement | −12,000 | −5,000 | −3,000 | — | — | |
| Change in accrued interest on short-term borrowings | — | −1 | 1 | — | — | |
| Prepaid expenses and other current assets | −998,000 | −356,000 | 852,000 | 268,000 | −586,000 | |
| Accounts payable, accrued expenses and related parties | 1 | 4 | −2 | — | — | |
| Net changes in operating lease | 117,000 | 43,000 | 8,000 | −93,000 | — | |
| Deferred revenues | −2 | — | −1 | — | — | |
| Deferred income | −105,000 | — | — | — | — | |
| Liability for employee rights upon retirement | 9,000 | 2,000 | 7,000 | −1,000 | 3,000 | |
| Deferred tax liabilities | 8 | — | — | — | — | |
| Other liabilities | −60,000 | −14,000 | — | — | — | |
| Total net cash used in operating activities | −9 | −8 | −10 | −28 | −21 | |
| Purchase of property and equipment | −9,000 | −18,000 | −254,000 | −496,000 | −375,000 | |
| Purchase of short-term deposits | −11 | −54 | −91 | −152 | −18 | |
| Purchase of marketable securities | −10 | — | — | — | — | |
| Investments at fair value | −65 | −1 | — | — | — | |
| Purchase of convertible note | −3 | — | — | — | — | |
| Proceeds from redemption of short-term deposits | 54 | 97 | 110 | 178 | — | |
| Exercise of Closing Penny Warrants and Subsequent Penny Warrants | — | −65,000 | — | — | — | |
| Proceeds from loan to an equity method investee | 6 | — | — | — | — | |
| Loan to investment in equity method | −7 | — | — | — | — | |
| Real estate investment | −2 | — | −100 | −3 | — | |
| Equity method investee | −250,000 | — | — | — | — | |
| Proceeds from long-term deposits | — | 5,000 | 5 | — | — | |
| Proceeds from marketable securities | 3 | — | — | — | — | |
| Proceeds from long-term investments and marketable securities | 40 | 65 | 5 | — | — | |
| Total net cash provided by investing activities | 5 | 106 | −73 | 30 | −24 | |
| Repurchase and retirement of common stock | −5 | −2 | — | — | — | |
| Loans repaid | — | −50 | −50 | — | — | |
| Tax withholdings related to stock-based compensation settlements | — | −2,000 | — | −783,000 | — | |
| Total net cash used in financing activities | −5 | −52 | 52 | 11 | 103 | |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | −30,000 | −4,000 | −54,000 | −64,000 | — | |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | −8 | 45 | −31 | 13 | 58 | |
| Interest paid | — | 2 | — | 2 | 563,000 | |
| Interest received | 5 | 7 | 5 | — | 563,000 | |
| 2024 Refinancing Tranche A | — | −22 | — | — | — | |
| 2024 Refinancing Tranche B | — | 25 | — | — | — | |
| Excise tax for repurchase and retirement of common stock | −15,000 | −10,000 | — | — | — | |
| Recognition of operating lease right-of-use assets and liabilities | 600,000 | 58,000 | — | — | — | |
| Waiver of loan granted to subsidiary | 952,000 | — | — | — | — | |
| Derecognition of right-of-use asset | — | −26,000 | — | — | — | |
| Derecognition of lease liability | — | 23,000 | — | — | — | |
| Purchases of marketable securities not yet settled | 254,000 | — | — | — | — | |
| Dividends declared but not yet paid in cash | 11 | — | — | — | — | |
| Warrants received from Alpha Tau | 3 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ORAMED PHARMACEUTICALS INC.'s CIK number?
ORAMED PHARMACEUTICALS INC.'s SEC CIK number is 0001176309 (1176309). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ORAMED PHARMACEUTICALS INC.'s SEC filings?
All of ORAMED PHARMACEUTICALS INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ORAMED PHARMACEUTICALS INC. last report earnings?
ORAMED PHARMACEUTICALS INC. (ORMP) most recently filed an earnings 8-K with the SEC on Nov 17, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-25-111310). This is ORAMED PHARMACEUTICALS INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ORAMED PHARMACEUTICALS INC.'s most recent earnings 8-K?
ORAMED PHARMACEUTICALS INC.'s latest earnings 8-K (Item 2.02) was filed Nov 17, 2025 under accession 0001213900-25-111310. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ORAMED PHARMACEUTICALS INC.'s latest earnings 8-K →
Look up any company's CIK number →